anti-ox40 agonist monoclonal antibody gen1055
Generic: Anti-OX40 Agonist Monoclonal Antibody GEN1055
anti-ox40 agonist monoclonal antibody gen1055: 1 clinical trial tracked.
anti-ox40 agonist monoclonal antibody gen1055 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about anti-ox40 agonist monoclonal antibody gen1055, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
Clinical Trial Registry Records (1)
First-In-Human, Open-Label, Dose Escalation Trial With Expansion Cohorts to Evaluate the Safety and Preliminary Efficacy of GEN1055 as Monotherapy and as Combination Therapy in Subjects With Malignant Solid Tumors
Primary endpoint: Dose Escalation: Number of Participants With Adverse Events (AEs)
Interventionalopen21 enrolledStarted 2024-05Completion 2025-114 sites · Spain, United StatesGenmab